Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsThree medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.
Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.
1.
A video animation guide to assist young people who are fatigued from cancer.
2.
PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer
3.
Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.
4.
The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.
5.
For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.
1.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
2.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
3.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
4.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
5.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
4.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge